The alpha-1 blocker naftopidil facilitated spontaneous expulsion of small ureteral stones in men, highlighting its potential in medical expulsive therapy (MET) for individuals with ureteral stones, a Japanese study has shown.
It is safe to use the RestoreX device for penile traction therapy for 30–90 minutes per day, with no serious adverse events reported, according to a study. The novel device significantly and clinically improves penile curvature and length, as well as erectile function, in men with Peyronie’s disease.
Oral solithromycin may not be a suitable substitute for ceftriaxone plus azithromycin in the first-line treatment of uncomplicated genital gonorrhoea, according to results of the phase III SOLITAIRE-U* trial.
New drug applications approved by US FDA as of 16 - 31 July 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Human papillomavirus (HPV) vaccination significantly reduces the frequency of genital HPV 16 and 18 infections and cervical intraepithelial neoplasia grade 2+ (CIN2+) in young women and shows signs of herd effects with a reduced frequency of anogenital warts in both young women and men, a recent study showed.
Patients undergoing assisted reproduction for non-male factor infertility do not derive greater benefit from intracytoplasmic sperm injection (ICSI) over in vitro fertilization (IVF), according to a study presented at ESHRE 2019.
A recent study comparing transperineal ultrasound-guided prostate biopsy (TPUSPB) with transrectal ultrasound-guided prostate biopsy (TRUSPB) showed that TPUSPB may be a good alternative in prostate cancer diagnosis.
Likelihood of pregnancy following artificial insemination by donor (AID) or in vitro fertilization (IVF) was not negatively affected by using sperm that had been cryopreserved for up to 15 years, according to a study from China.
Use of complementary and alternative medicine (CAM) is common among patients with prostate cancer and has seen an increase among those who are newly diagnosed with the disease, a study has shown. Multivitamins and omega-3 fatty acids are the most commonly used CAMs from 1996 to 2016, while vitamin D use has increased dramatically from 2006 to 2010.
Cabozantinib was no better than the combination of mitoxantrone and prednisone for pain relief in heavily pretreated men with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, according to the findings of the COMET-2* trial.